Annual Report

Overview

The report describes BioPorto's response to COVID-19, including development of gRAD-based kidney and SARS-CoV-2 tests. NGALds obtained a CE mark while the COVID-19 test advanced to clinical evaluation. Two rights issues raised over DKK 130 million to support upcoming milestones, while group revenue was DKK 23.2 million versus DKK 26.6 million in 2019.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2020
Period: 1 January 2020 – 31 December 2020
Language: English
Pages
File size

Standards

Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services